프로게스토겐 개요
Progestogens remain one of the most fiercely debated topics in transgender female HRT. Unlike estrogen and anti-androgens, progestogens are not a mandatory component of feminizing hormone therapy. The major international clinical guidelines maintain a highly cautious stance regarding their widespread use [1] [2] .
The Debate & Current Evidence
섹션 제목: “The Debate & Current Evidence”Arguments FOR Progesterone
섹션 제목: “Arguments FOR Progesterone”- Breast Volume/Shape: Research by Prior (2019) suggests that introducing progesterone later in HRT might improve the subjective “roundness” and fullness of breast development by maturing the lobuloalveolar tissue [5] . However, this study relied on patients’ self-reported satisfaction and did not include objective measurements of breast volume.
- Sleep Improvement: Micronized progesterone possesses a heavy sedative effect. For transgender women suffering from insomnia, taking it before bed drastically improves sleep architecture [5] .
- Mood Stabilization: Many users report that progesterone levels out their emotional volatility, though rigorous controlled studies backing this specific to transgender women are currently lacking.
Arguments AGAINST (Or Urging Caution)
섹션 제목: “Arguments AGAINST (Or Urging Caution)”- The Endocrine Society 2017 Guidelines explicitly state there is insufficient clinical evidence to warrant the routine prescription of progestogens in transgender HRT [1] .
- WPATH SOC 8 maintains the same highly cautious stance, refusing to list it as a standard requirement [2] .
- Synthetic progestins (including the progestogenic effect of high-dose CPA) are definitively linked to heightened breast cancer and VTE risks [4] .
- There are still exactly zero high-quality Randomized Controlled Trials (RCTs) proving that progesterone organically increases breast cup size in trans women.
Bioidentical vs. Synthetic Progestogens
섹션 제목: “Bioidentical vs. Synthetic Progestogens”| Feature | Bioidentical Micronized Progesterone | Synthetic Progestins (MPA, etc.) |
|---|---|---|
| Common Brands | Prometrium, Utrogestan | Provera (MPA), NETA, Levonorgestrel |
| Chemical Structure | Identical to human biological progesterone | Chemically altered; metabolizes differently |
| VTE Risk | Early data suggests far lower risk than synthetics | Significantly increases blood clot risks |
| Breast Cancer Risk | Short-term data implies lower risk | WHI study proved severe risk increase |
| Sedative Effect | Heavy (Excellent for sleep aid) | None, or acts completely differently |
| Recommendation | The ONLY acceptable option if choosing to use a progestogen | NEVER use for transgender HRT |
Preliminary evidence indicates that bioidentical micronized progesterone carries a distinctly lower VTE (clot) risk compared to synthetics [6] . This makes it infinitely superior.
Strategic Timing Recommendations
섹션 제목: “Strategic Timing Recommendations”If, after understanding the massive gaps in clinical data, you still wish to trial progesterone, follow these rigid safety rules:
- Wait at least 12 months: Let estrogen build the ductal branches first. Do not ruin your potential by rushing. Wait until Tanner Stage III [3] .
- Accept only Bioidentical: Demand Micronized Progesterone (Prometrium/Utrogestan).
- Start Low: Begin at 100 mg/day, taken immediately before bed.
- Monitor Everything: Assess your mood, breast tenderness, and sleep quality 4 to 8 weeks after starting.
- More is not Better: If 100mg does nothing, jumping to 400mg isn’t going to magically force breast growth.
References
- Hembree WC et al. Endocrine Treatment of Gender-Dysphoric/Gender-Incongruent Persons. J Clin Endocrinol Metab 2017;102(11):3869-3903. DOI:10.1210/jc.2017-01658
- Coleman E et al. Standards of Care for the Health of Transgender and Gender Diverse People, Version 8. Int J Transgend Health 2022;23(S1):S1-S259. DOI:10.1080/26895269.2022.2100644
- Patel et al. Breast Development in Transgender Women on Hormone Therapy. 2021. PMC8664122
- Vinogradova Y et al. Use of hormone replacement therapy and risk of venous thromboembolism. BMJ 2019.
- Prior JC. Progesterone is important for transgender women’s therapy — applying evidence for the benefits of progesterone in ciswomen. J Clin Endocrinol Metab 2019;104(4):1181-1186. DOI:10.1210/jc.2018-01777
- Canonico M et al. Hormone therapy and venous thromboembolism: an updated overview. Climacteric 2018.